In addition, other studies have found that PTH and CTX decreased, and OSTEOC increased with 12 weeks of escitalopram treatment in premenopausal female participants with newly diagnosed depression (37), while 8 weeks of escitalopram treatment does not significantly alter bone turnover markers in peri- or postmenopausal non-depressed women (38). This evidence concerns the gene PTH and major depressive disorder.